Author:
Yehia Ali M.,Sami Iman,Riad Safa’a M.,El-Saharty Yasser S.
Publisher
Springer Science and Business Media LLC
Subject
Organic Chemistry,Clinical Biochemistry,Biochemistry,Analytical Chemistry
Reference19 articles.
1. Andersson KE, Chapple CR (2011) Current pharmacotherapy of lower urinary tract symptoms. Surgery (Oxford) 29:260–264
2. Novara G, Cornu JN (2013) Mirabegron as a new class of oral drug for overactive bladder syndrome: many positive perspectives, some concerns. Eur Urol 63:306–308
3. Görög S (2000) Identification and determination of impurities in drugs. Elsevier, Amsterdam
4. Bhimanadhuni CN, Garikapati DR (2012) RP HPLC method for the determination of mirabegron in pharmaceutical dosage form. Am J Pharm Tech Res 2:565–571
5. Rajan N, Anverbasha K (2014) Development and validation of a LC method for the enantiomeric purity determination of S-mirabegron in a pharmaceutical drug substance using a amylose immobilised based chiral stationary phase. Am J PharmTech Res 4:434–441
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献